Group 1 - Zhongyuan Expressway (600020) expects a net profit of approximately 612 million yuan for 2025, a decrease of about 30% year-on-year [1] - Bomin Electronics (603936) anticipates a net profit of 15 million to 22 million yuan for 2025, achieving a turnaround from loss to profit compared to the previous year [2] - Fangda Special Steel (600507) forecasts a net profit of 835 million to 998 million yuan for 2025, an increase of 236.9% to 302.67% year-on-year [3] Group 2 - Jiadu Technology (600728) expects a net profit of 160 million to 200 million yuan for 2025, recovering from a loss of 115 million yuan in the previous year [4] - Changyang Technology (688299) predicts a net loss of 116 million to 168 million yuan for 2025 [5] - Zhongzi Technology (688737) anticipates a net loss of 45.24 million to 67.86 million yuan for 2025 [6] Group 3 - Two-sided Needle (600249) expects a net profit of 5 million to 10 million yuan for 2025, a decline of 87.67% to 93.83% year-on-year [7] - Sanrenxing (605168) forecasts a net profit of 181 million to 209 million yuan for 2025, an increase of 46.79% to 69.5% year-on-year [8] - Shubeide (300322) anticipates a net profit of 60 million to 70 million yuan for 2025, recovering from a loss of 64.46 million yuan in the previous year [9] Group 4 - Maoye Commercial (600828) expects a net loss of 201 million to 242 million yuan for 2025 [10] - Hongsheng Huayuan (601096) forecasts a net profit of 348 million to 400 million yuan for 2025, an increase of 51.22% to 73.82% year-on-year [11] - Huafeng Technology (688629) anticipates a net profit of 338 million to 388 million yuan for 2025, achieving a turnaround from loss to profit [12] Group 5 - Aerospace Rainbow (002389) expects a net profit of 25 million to 31 million yuan for 2025, a decrease of 64.84% to 71.65% year-on-year [14] - Shangong Shenbei (600843) predicts a net loss of 120 million to 150 million yuan for 2025, compared to a loss of 244 million yuan in the previous year [15] - Chaoxun Communication (603322) anticipates a net profit of 36 million to 54 million yuan for 2025, achieving a turnaround from loss to profit [16] Group 6 - Guannong Co. (600251) expects a net profit of 330 million to 340 million yuan for 2025, an increase of 61.29% to 66.18% year-on-year [17] - Shandong Steel (600022) forecasts a net profit of around 100 million yuan for 2025, recovering from a loss of 2.891 billion yuan in the previous year [18] - Baili Technology (603959) anticipates a net loss of 140 million to 200 million yuan for 2025 [19] Group 7 - Electric Power Investment Hydropower (600292) expects a net profit of approximately 517 million yuan for 2025, a year-on-year increase of about 1337% [20] - Aibulu (301259) forecasts a net profit of 26 million to 33.8 million yuan for 2025, recovering from a loss of 30.84 million yuan in the previous year [21] - Yipin Hong (300723) announced that its subsidiary received approval for clinical trials of a new drug [22] Group 8 - Meixin Sheng (688458) plans to acquire 100% equity of Xinyan Micro for 160 million yuan [23][24] - Lanshi Heavy Industry (603169) expects a net loss of 370 million to 440 million yuan for 2025, transitioning from profit to loss [25] - Hongyang (000525) anticipates a net loss of 260 million to 390 million yuan for 2025, compared to a profit of 388 million yuan in the previous year [26] Group 9 - Tianzhihang (688277) predicts a net loss of 165 million to 198 million yuan for 2025, with losses expected to widen by 36.22% to 63.46% compared to the previous year [27] - Tongda Co. (002560) announced plans for a major shareholder to reduce holdings by no more than 1% [28] - *ST Chengchang (001270) expects a net profit of 95 million to 124 million yuan for 2025, recovering from a loss of 31.12 million yuan in the previous year [29] Group 10 - Yirui Technology (688301) reported a net profit of 661 million yuan for 2025, a year-on-year increase of 42.15% [30] - Hualitai (001217) anticipates a net loss of 28 million to 38 million yuan for 2025, transitioning from profit to loss [31] - Yunjiji Group (001288) expects a net profit of 220 million to 252 million yuan for 2025, a year-on-year increase of 40% to 60% [32] Group 11 - Heertai (002402) forecasts a net profit of 638 million to 729 million yuan for 2025, an increase of 75% to 100% year-on-year [33] - Shenhao Technology (300853) anticipates a net loss of 185 million to 220 million yuan for 2025, compared to a loss of 238 million yuan in the previous year [34] - Zhongyan Dadi (003001) expects a net profit of 10 million to 15 million yuan for 2025, a decline of 75.97% to 83.98% year-on-year [35] Group 12 - Landai Technology (002765) forecasts a net profit of 180 million to 200 million yuan for 2025, a year-on-year increase of 44.83% to 60.93%, with a non-recurring profit of 140 million to 160 million yuan, an increase of 113.1% to 143.54% [37] - Yingfeite (300582) plans to raise product prices by 5% to 15% starting March 1, 2026, due to rising raw material costs [38] - Lanzhou Bank (001227) plans to distribute 285 million yuan in cash dividends for the 2025 interim profit distribution [39] Group 13 - Wancheng Group (300972) announced plans for shareholders to reduce holdings by no more than 1.27% [40] - *ST Huarong (600421) expects to turn a profit in 2025, with a projected net profit of 6.5 million to 8 million yuan [41] - Jiaheng Home (300955) anticipates a net loss of 29 million to 39 million yuan for 2025, compared to a loss of 23.69 million yuan in the previous year [42] Group 14 - Aide Biology (300685) announced plans for a major shareholder to reduce holdings by no more than 1.22% [43] - Haixia Innovation (300300) expects a net profit of 100 million to 150 million yuan for 2025, a year-on-year increase of 1660.56% to 2540.85% [44]

Core Viewpoint - The surgical robot industry is experiencing accelerated commercialization driven by both policy support and increasing demand [1][2] Group 1: Company Performance - Tianzhihang, known as the "first stock of surgical robots," forecasts a revenue of 270 million to 300 million yuan for 2025, representing a growth of 50.97% to 67.75% compared to the previous year [1] - The company expects a net loss attributable to shareholders of 165 million to 198 million yuan, which is an increase in losses compared to the previous year [1] - The significant revenue growth is attributed to a recovering market environment and increased sales and technical service income [1] Group 2: Market Dynamics - The Tianji orthopedic surgical robot is projected to perform over 49,000 surgeries in 2025, continuing growth from 39,000 surgeries in 2024, with a cumulative total exceeding 150,000 surgeries [1] - The acceptance of surgical robots in the industry is increasing due to advancements by leading manufacturers in technology, service, product maturity, and business models [2] - The orthopedic surgical robot segment is recognized as one of the more mature areas within the surgical robot market, maintaining a leading position in commercialization [2] Group 3: Industry Trends - The domestic market for orthopedic surgical robots is expected to see over 100 units awarded in procurement by 2025, with a market growth rate of approximately 35% year-on-year [2] - Tianzhihang holds a leading market share of over 40% in the domestic orthopedic surgical robot market [2] - Recent policy changes, including a unified pricing framework for robotic surgeries, are anticipated to provide systemic support for the entire surgical robot industry, with orthopedic surgical robots likely to be the primary beneficiaries due to strong clinical demand and a large patient base [2]

证券代码：688277 证券简称：天智航 公告编号：2026-005 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 1、 经财务部门初步测算，预计2025年度实现营业收入27,000.00万元至30,000.00万元，与上年同期相比 增长50.97%至67.75%，2025年度归属于母公司所有者的净利润为亏损16,500.00万元至亏损19,800.00万 元，与上年同期相比亏损增加4,387.03万元至7,687.03万元，较上年同期亏损扩大36.22%至63.46%。 2、 预计2025年度实现归属于母公司所有者扣除非经常性损益后的净利润为亏损20,000.00万元至亏损 23,300.00万元，与上年同期相比亏损增加3,025.53万元至6,325.53万元，较上年同期亏损扩大17.82%至 37.26%。 （三）本次业绩预告情况未经注册会计师审计。 2、报告期内，天玑骨科手术机器人开展的手术数量超过4.9万 ...

报告期内，归属于母公司所有者的净利润、归属于母公司所有者扣除非经常性损益的净利润亏损较上年 同期有所扩大，主要原因为：投资收益较上年同期有较大幅度减少；因实施限制性股票激励计划，股份 支付费用较上年同期有较大幅度增长；冲回以前年度确认的亏损部分的递延所得税费用，导致所得税费 用较上年同期有所增长。上述影响归属于母公司所有者的净利润亏损扩大约8,900.00万元。 预计2025年度实现归属于母公司所有者扣除非经常性损益后的净利润为亏损20,000.00万元至亏损 23,300.00万元，与上年同期相比亏损增加3,025.53万元至6,325.53万元，较上年同期亏损扩大17.82%至 37.26%。 报告期内，营业收入实现较大幅度增长，主要原因为：行业市场环境回暖，产品销售及技术服务收入实 现较大幅度增长。 格隆汇1月28日丨天智航(688277.SH)公布，经财务部门初步测算，预计2025年度实现营业收入27,000.00 万元至30,000.00万元，与上年同期相比增长50.97%至67.75%，2025年度归属于母公司所有者的净利润 为亏损16,500.00万元至亏损19,800.00万元，与上年同期相比 ...

格隆汇1月28日｜天智航(688277.SH)公告称，天智航预计2025年度归属于母公司所有者的净利润为亏损 1.65亿元至1.98亿元，较上年同期亏损扩大。业绩变动主要原因：投资收益大幅减少；实施限制性股票 激励计划致股份支付费用大幅增长；冲回以前年度确认亏损部分的递延所得税费用，导致所得税费用增 长。 ...

Core Viewpoint - Tianzhihang (688277) is expected to report a net profit loss of between 165 million to 198 million yuan for 2025, indicating an increase in losses compared to the previous year, with a projected increase of 43.87 million to 76.87 million yuan, representing a year-on-year loss expansion of 36.22% to 63.46% [1] Group 1 - The industry market environment is recovering, leading to significant growth in product sales and technical service revenue [1] - The increase in net profit loss compared to the previous year is primarily due to a substantial decrease in investment income [1] - The implementation of a restricted stock incentive plan has resulted in a significant increase in share-based payment expenses compared to the previous year [1] Group 2 - The reversal of previously recognized losses has led to an increase in deferred income tax expenses, contributing to the growth in income tax expenses compared to the previous year [1] - The combined impact of these factors has resulted in an approximate increase of 89 million yuan in the expanded net profit loss [1]

用状态日期调整至 2027 年 12 月。 三、本次使用部分闲置募集资金临时补充流动资金的计划 中信建投证券股份有限公司 关于北京天智航医疗科技股份有限公司 使用部分暂时闲置募集资金临时补充流动资金事项的核查 意见 中信建投证券股份有限公司（以下简称"中信建投证券"或"保荐人"）作 为北京天智航医疗科技股份有限公司（以下简称"天智航"或"公司"）2021 年 度向特定对象发行 A 股股票的保荐人，根据《证券发行上市保荐业务管理办法》 《上市公司募集资金监管规则》《上海证券交易所科创板股票上市规则》《上海证 券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关规定，对天 智航使用部分暂时闲置募集资金临时补充流动资金事项进行了审慎核查，核查情 况及核查意见如下： 一、募集资金基本情况 | 发行名称 | | | | | 2021年度向特定对象发行A股股票 | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 募集资金总额 | 37,020.00 | | | 万元 | | | | | 募集资金净额 | 35,975.66 | | | 万元 | ...

北京天智航医疗科技股份有限公司 证券代码：688277 证券简称：天智航 公告编号：2026-004 关于使用部分暂时闲置募集资金临时补充流动资金的公告 补流期限：自 2026 年 1 月 28 日第六届董事会第二十八次会议审议通 过之日起不超过 12 个月 北京天智航医疗科技股份有限公司（以下简称"公司"）于 2026 年 1 月 28 日召开第六届董事会第二十八次会议，审议通过了《关于使用部分暂时闲置募集 资金临时补充流动资金的议案》，同意公司使用不超过 7,000.00 万元（含本数） 暂时闲置募集资金用于临时补充流动资金，使用期限自公司董事会审议通过之日 起不超过 12 个月。保荐人对上述事项出具了明确无异议的核查意见。现将相关 事项公告如下： | 发行名称 | 2021 | | | 年度向特定对象发行 | A | 股股票 | | --- | --- | --- | --- | --- | --- | --- | | 募集资金总额 | 37,020.00 | | 万元 | | | | | 募集资金净额 | 35,975.66 | | 万元 | | | | | 募集资金到账时间 | 2023 2 | 年 ...

（一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 1、经财务部门初步测算，预计 2025 年度实现营业收入 27,000.00 万元至 30,000.00 万元，与上年同期相比增长 50.97%至 67.75%，2025 年度归属于母公 司所有者的净利润为亏损 16,500.00 万元至亏损 19,800.00 万元，与上年同期相比 亏损增加 4,387.03 万元至 7,687.03 万元，较上年同期亏损扩大 36.22%至 63.46%。 证券代码：688277 证券简称：天智航 公告编号：2026-005 北京天智航医疗科技股份有限公司 2025 年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 四、风险提示 公司不存在影响本次业绩预告内容准确性的重大不确定因素，本次业绩预告 未经注册会计师审计。 五、其他说明事项 2、预计 2025 年度实现归属于母公司所有者扣除非经常性损益后的净利润 为亏损 20,000.00 万元至亏损 ...

天智航公告，预计2025年度归属于母公司所有者的净亏损为1.65亿元至1.98亿元，与上年同期相比亏损 增加4387.03万元至7687.03万元，较上年同期亏损扩大36.22%至63.46%。预计2025年度实现归属于母公 司所有者扣除非经常性损益后的净亏损为2亿元至2.33亿元，与上年同期相比亏损增加3025.53万元至 6325.53万元，较上年同期亏损扩大17.82%至37.26%。报告期内，营业收入实现较大幅度增长，主要原 因为：行业市场环境回暖，产品销售及技术服务收入实现较大幅度增长。 ...